1. Phylogeny  
Tyrosine‐protein kinase JAK2 is a member of the Janus kinase family, which also comprises JAK1, JAK3, and TYK2, and is evolutionarily conserved among vertebrates and other metazoans (lin2018anovelselective pages 1-2, perner2019rolesofjak2 pages 1-3). JAK2 orthologs are found in all mammalian species and can be traced back to a common ancestor of eukaryotes that possessed a rudimentary non‐receptor tyrosine kinase; this places JAK2 within the core set of kinases essential for cytokine signaling (perner2019rolesofjak2 pages 1-3, bandaranayake2012crystalstructuresof pages 1-2). As a member of the JAK family, its domain organization and functional properties are shared with its paralogs, yet unique regulatory sequence features, such as those within its pseudokinase domain, distinguish it from other tyrosine kinases in the human kinome (lin2018anovelselective pages 1-2).

2. Reaction Catalyzed  
JAK2 catalyzes the transfer of the gamma‐phosphate group from ATP to specific tyrosine residues on substrate proteins, following the reaction: ATP + [protein]-OH → ADP + [protein]-O‑phosphotyrosine + H⁺ (bandaranayake2012crystalstructuresof pages 1-2, hubbard2018mechanisticinsightsinto pages 1-2). This phosphoryl transfer is central to its role in cytokine receptor signaling, where the phosphorylation events create docking sites for downstream signal transducers such as STAT proteins (hubbard2018mechanisticinsightsinto pages 1-2).

3. Cofactor Requirements  
The catalytic activity of JAK2 is strictly dependent on ATP as a phosphate donor and requires divalent metal ions, predominantly Mg²⁺, to stabilize the binding of ATP within the active site of its kinase domain (min2015structuralandfunctional pages 2-3). The requirement for Mg²⁺ is consistent with the behavior of many protein kinases where the metal ion serves both to neutralize the charge on the phosphate groups and to facilitate nucleophilic attack by the substrate hydroxyl group (min2015structuralandfunctional pages 2-3).

4. Substrate Specificity  
JAK2 exhibits substrate specificity for the phosphorylation of tyrosine residues present on the cytoplasmic regions of cytokine receptors as well as on STAT proteins that dock onto these receptors following ligand binding. Through its action, it creates phosphotyrosine motifs that serve as binding sites for recruitment and subsequent phosphorylation of STAT transcription factors, thereby instigating the downstream JAK/STAT signaling cascade (qian2011nuclearjak2form pages 1-2, hubbard2018mechanisticinsightsinto pages 1-2).

5. Structure  
JAK2 is organized into a series of functional domains that include an N‑terminal FERM domain responsible for receptor association, a central SH2-like domain implicated in structural stabilization, a pseudokinase domain (JH2) that regulates the kinase activity, and a C‑terminal catalytic kinase domain (JH1) that executes the phosphoryl transfer reaction (bandaranayake2012crystalstructuresof pages 1-2, hubbard2018mechanisticinsightsinto pages 1-2). The FERM domain anchors JAK2 to the intracellular segment of type I and type II cytokine receptors, thereby localizing the kinase to sites of receptor activation (bandaranayake2012crystalstructuresof pages 1-2). The adjoining SH2-like domain, while not exhibiting classical phosphotyrosine binding, contributes to overall protein stability and may assist in subtle aspects of substrate orientation.  
The central pseudokinase domain (JH2) adopts a eukaryotic protein kinase fold comprised of a smaller N‑lobe with a five‑stranded β‑sheet and a single αC helix, along with a predominantly α‑helical C‑lobe. Despite retaining the structural framework typical of kinases, the JH2 domain does not contain all conserved catalytic residues and instead binds Mg‑ATP in a non‐canonical manner with high affinity, thereby serving a critical regulatory function rather than acting as a major phosphotransfer enzyme (silvennoinen2013newinsightsinto pages 2-3). Notably, the common pathogenic mutation V617F is located in the β4‑β5 loop of the JH2 domain and is associated with significant conformational alterations, including the rigidification of the αC helix through π‑stacking interactions with adjacent phenylalanine residues (bandaranayake2012crystalstructuresof pages 6-7, lupardus2014structureofthe pages 5-6).  
The C‑terminal kinase domain (JH1) displays all canonical features of a tyrosine kinase, with an ATP‑binding pocket, an activation loop, and a conserved glycine-rich loop that underpins its catalytic activity. In this domain, the proper alignment of the αC helix and the activation loop is crucial to form a hydrophobic spine that stabilizes the active conformation of the enzyme, thereby enabling the efficient transfer of phosphate groups to substrate tyrosine residues (williams2009dissectingspecificityin pages 5-7, min2015structuralandfunctional pages 8-10). The structural interplay and precise spatial configuration between the pseudokinase and kinase domains are essential for maintaining the basal inhibitory state of JAK2, while still permitting full activation in response to appropriate extracellular signals (lupardus2014structureofthe pages 1-2).

6. Regulation  
JAK2 is subject to intricate regulatory mechanisms that control its catalytic activity and ensure appropriate signal transduction. A key component of this regulation is the autoinhibitory interaction mediated by the pseudokinase domain (JH2), which suppresses the activity of the catalytic kinase domain (JH1) under basal conditions (hubbard2018mechanisticinsightsinto pages 3-5). This autoinhibition is reinforced by constitutive phosphorylation events within the JH2 domain at residues such as Ser523 and Tyr570, which collectively contribute to maintaining a low basal kinase activity state (bandaranayake2012crystalstructuresof pages 7-9, silvennoinen2013newinsightsinto pages 3-5).  
Upon cytokine binding to receptors, a conformational change is induced that relieves the inhibitory constraints imposed by the pseudokinase domain, allowing the kinase domain to undergo trans-phosphorylation on critical activation loop tyrosine residues and thus become fully active (hubbard2018mechanisticinsightsinto pages 5-6, perner2019rolesofjak2 pages 3-5). Mutations such as V617F impair the normal autoinhibitory function of the JH2 domain by stabilizing the stimulatory conformation of the αC helix, thereby resulting in ligand-independent activation of JAK2 and aberrant downstream signaling (vainchenker2005auniqueactivating pages 1-2, bandaranayake2012crystalstructuresof pages 6-7). In addition, various post-translational modifications, including further phosphorylation events and ubiquitination, play roles in fine-tuning JAK2’s activity, stability, and turnover (hubbard2018mechanisticinsightsinto pages 6-7, silvennoinen2013newinsightsinto pages 3-5). Allosteric regulation through conformational shifts and domain–domain interactions also contributes to the dynamic balance between inactive and active states of JAK2 (kesarwani2015targetingsubstratesitein pages 17-18).

7. Function  
JAK2 is centrally involved in mediating signal transduction initiated by cytokine and growth factor receptors. Upon ligand binding, receptors undergo dimerization or conformational rearrangements that bring JAK2 molecules into close proximity, whereby JAK2 phosphorylates specific tyrosine residues on the receptor cytoplasmic tails (qian2011nuclearjak2form pages 1-2, hubbard2018mechanisticinsightsinto pages 1-2). These phosphorylated sites then serve as docking sites for STAT transcription factors, which become phosphorylated by JAK2, dimerize, and translocate to the nucleus to regulate the transcription of genes involved in cell proliferation, differentiation, and survival (hubbard2018mechanisticinsightsinto pages 1-2).  
Beyond its canonical role at the plasma membrane, JAK2 has also been detected in the nuclear compartment where it is implicated in direct regulation of gene transcription and potentially histone modification, thereby extending its function to the modulation of chromatin structure (qian2011nuclearjak2form pages 7-7). JAK2 expression is ubiquitous, with particularly high levels in hematopoietic tissues, underscoring its vital role in blood cell development and immune responses. In the context of innate and adaptive immunity, JAK2 is required for the efficient transmission of cytokine-mediated signals, serving as a critical mediator for receptors such as those for erythropoietin, thrombopoietin, and various interleukins (perner2019rolesofjak2 pages 1-3, hubbard2018mechanisticinsightsinto pages 1-2).  
The biological importance of JAK2 is further highlighted by its involvement in pathological conditions; for instance, mutations such as V617F lead to constitutive activation of the kinase, which is a hallmark of myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, and primary myelofibrosis (vainchenker2005auniqueactivating pages 1-2, lin2018anovelselective pages 1-2). These mutations drive uncontrolled cell proliferation and are associated with alterations in downstream STAT signaling, thereby contributing to neoplastic transformation and disease progression (perner2019rolesofjak2 pages 5-7).

8. Other Comments  
A number of small molecule inhibitors have been developed to target JAK2 activity in pathological states. Clinically approved inhibitors such as ruxolitinib and fedratinib are used to treat myeloproliferative neoplasms by competitively inhibiting ATP binding in the JH1 kinase domain, although these compounds may also affect other JAK family members due to the high structural conservation in the active site (lin2018anovelselective pages 10-11, williams2009dissectingspecificityin pages 12-13). Recent efforts have also focused on targeting the substrate-binding site as an alternative approach to prevent the emergence of inhibitor-resistant mutations, a strategy supported by studies mapping mutations and exploring novel binding modalities (kesarwani2015targetingsubstratesitein pages 17-18, kesarwani2015targetingsubstratesitein pages 18-19).  
The oncogenic V617F mutation in JAK2, which disrupts the autoinhibitory function of the pseudokinase domain, remains the most notable genetic alteration associated with JAK2-driven diseases and has been extensively used as both a diagnostic marker and a therapeutic target in conditions such as polycythemia vera (vainchenker2005auniqueactivating pages 1-2, bandaranayake2012crystalstructuresof pages 6-7). Furthermore, the dual subcellular localization of JAK2, with roles in both cytoplasmic signal transduction and nuclear transcriptional regulation, underscores the multifaceted nature of its function and the complexity of its regulation (qian2011nuclearjak2form pages 3-5, perner2019rolesofjak2 pages 7-9).

9. References  
1. OpenTargets Search: -JAK2. Open Targets Platform, as referenced in the context provided.  
2. Bandaranayake, R. M., Ungureanu, D., Shan, Y., Shaw, D. E., Silvennoinen, O., & Hubbard, S. R. (2012). Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nature Structural & Molecular Biology, 19, 754-759. (bandaranayake2012crystalstructuresof pages 1-2, 6-7, 7-9, 13-16)  
3. Hubbard, S. R. (2018). Mechanistic insights into regulation of JAK2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. (hubbard2018mechanisticinsightsinto pages 1-2, 2-3, 3-5, 5-6, 6-7)  
4. Kesarwani, M., Huber, E., Kincaid, Z., Evelyn, C. R., Biesiada, J., Rance, M., Thapa, M., Shah, N., Meller, J., Zheng, Y., & Azam, M. (2015). Targeting substrate-site in JAK2 kinase prevents emergence of genetic resistance. Scientific Reports, Sep 2015. (kesarwani2015targetingsubstratesitein pages 2-4, 5-7, 17-18, 18-19, 13-14)  
5. Lin, T. E., HuangFu, W.-C., Chao, M.-W., Sung, T.-Y., Chang, C.-D., Chen, Y.-Y., Hsieh, J.-H., Tu, H.-J., Huang, H.-L., Pan, S.-L., & Hsu, K.-C. (2018). A novel selective JAK2 inhibitor identified using pharmacological interactions. Frontiers in Pharmacology, Dec 2018. (lin2018anovelselective pages 1-2, 10-11, 13-13)  
6. Lupardus, P. J., Ultsch, M., Wallweber, H., Kohli, P. B., Johnson, A. R., & Eigenbrot, C. (2014). Structure of the pseudokinase–kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proceedings of the National Academy of Sciences, 111, 8025-8030. (lupardus2014structureofthe pages 1-2, 3-4, 4-5, 5-6)  
7. Vainchenker, W., & Constantinescu, S. N. (2005). A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology, 2005:195-200. (vainchenker2005auniqueactivating pages 1-2, 2-3, 5-6, 6-6)  
8. Williams, N. K., Bamert, R. S., Patel, O., Wang, C., Walden, P. M., Wilks, A. F., Fantino, E., Rossjohn, J., & Lucet, I. S. (2009). Dissecting specificity in the Janus kinases: the structures of JAK‐specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. Journal of Molecular Biology, 387, 219-232. (williams2009dissectingspecificityin pages 1-3, 5-7, 12-13, 13-14)  
9. Min, X., Ungureanu, D., Maxwell, S., Hammarén, H., Thibault, S., Hillert, E.-K., Ayres, M., Greenfield, B., Eksterowicz, J., Gabel, C., Walker, N., Silvennoinen, O., & Wang, Z. (2015). Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2). Journal of Biological Chemistry, 290, 27261-27270. (min2015structuralandfunctional pages 1-2, 7-8, 8-10, 11-13, 2-3)  
10. Perner, F., Perner, C., Ernst, T., & Heidel, F. H. (2019). Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells, 8, 854. (perner2019rolesofjak2 pages 1-3, 3-5, 5-7, 7-9, 10-12, 19-19)  
11. Puleo, D. E., Kucera, K., Hammarén, H. M., Ungureanu, D., Newton, A. S., Silvennoinen, O., Jorgensen, W. L., & Schlessinger, J. (2017). Identification and characterization of JAK2 pseudokinase domain small molecule binders. ACS Medicinal Chemistry Letters, 8, 618-621. (puleo2017identificationandcharacterization pages 4-4)  
12. Qian, C.-J., Yao, J., & Si, J.-M. (2011). Nuclear JAK2: Form and function in cancer. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology, Sep 2011. (qian2011nuclearjak2form pages 1-2, 3-5, 7-7, 13-14)  
13. Silvennoinen, O., Ungureanu, D., Niranjan, Y., Hammaren, H., Bandaranayake, R., & Hubbard, S. R. (2013). New insights into the structure and function of the pseudokinase domain in JAK2. Biochemical Society Transactions, 41(4), 1002-1007. (silvennoinen2013newinsightsinto pages 1-2, 2-3, 3-5, 5-5)

References

1. (OpenTargets Search: -JAK2): Open Targets Query (-JAK2, 25 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (bandaranayake2012crystalstructuresof pages 1-2): Rajintha M Bandaranayake, Daniela Ungureanu, Yibing Shan, David E Shaw, Olli Silvennoinen, and Stevan R Hubbard. Crystal structures of the jak2 pseudokinase domain and the pathogenic mutant v617f. Nature Structural &amp; Molecular Biology, 19:754-759, Jul 2012. URL: https://doi.org/10.1038/nsmb.2348, doi:10.1038/nsmb.2348. This article has 287 citations.

3. (hubbard2018mechanisticinsightsinto pages 1-2): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.

4. (hubbard2018mechanisticinsightsinto pages 3-5): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.

5. (hubbard2018mechanisticinsightsinto pages 5-6): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.

6. (hubbard2018mechanisticinsightsinto pages 6-7): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.

7. (kesarwani2015targetingsubstratesitein pages 17-18): M. Kesarwani, E. Huber, Zachary Kincaid, Chris R. Evelyn, J. Biesiada, M. Rance, M. Thapa, N. Shah, J. Meller, Yi Zheng, and M. Azam. Targeting substrate-site in jak2 kinase prevents emergence of genetic resistance. Scientific Reports, Sep 2015. URL: https://doi.org/10.1038/srep14538, doi:10.1038/srep14538. This article has 65 citations and is from a poor quality or predatory journal.

8. (kesarwani2015targetingsubstratesitein pages 18-19): M. Kesarwani, E. Huber, Zachary Kincaid, Chris R. Evelyn, J. Biesiada, M. Rance, M. Thapa, N. Shah, J. Meller, Yi Zheng, and M. Azam. Targeting substrate-site in jak2 kinase prevents emergence of genetic resistance. Scientific Reports, Sep 2015. URL: https://doi.org/10.1038/srep14538, doi:10.1038/srep14538. This article has 65 citations and is from a poor quality or predatory journal.

9. (lupardus2014structureofthe pages 1-2): Patrick J. Lupardus, Mark Ultsch, Heidi Wallweber, Pawan Bir Kohli, Adam R. Johnson, and Charles Eigenbrot. Structure of the pseudokinase–kinase domains from protein kinase tyk2 reveals a mechanism for janus kinase (jak) autoinhibition. Proceedings of the National Academy of Sciences, 111:8025-8030, May 2014. URL: https://doi.org/10.1073/pnas.1401180111, doi:10.1073/pnas.1401180111. This article has 228 citations.

10. (min2015structuralandfunctional pages 8-10): Xiaoshan Min, Daniela Ungureanu, Sarah Maxwell, Henrik Hammarén, Steve Thibault, Ellin-Kristina Hillert, Merrill Ayres, Brad Greenfield, John Eksterowicz, Chris Gabel, Nigel Walker, Olli Silvennoinen, and Zhulun Wang. Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290:27261-27270, Nov 2015. URL: https://doi.org/10.1074/jbc.m115.672048, doi:10.1074/jbc.m115.672048. This article has 108 citations and is from a domain leading peer-reviewed journal.

11. (perner2019rolesofjak2 pages 3-5): Florian Perner, Caroline Perner, Thomas Ernst, and Florian H. Heidel. Roles of jak2 in aging, inflammation, hematopoiesis and malignant transformation. Cells, 8:854, Aug 2019. URL: https://doi.org/10.3390/cells8080854, doi:10.3390/cells8080854. This article has 226 citations and is from a peer-reviewed journal.

12. (puleo2017identificationandcharacterization pages 4-4): David E. Puleo, Kaury Kucera, Henrik M. Hammarén, Daniela Ungureanu, Ana S. Newton, Olli Silvennoinen, William L. Jorgensen, and Joseph Schlessinger. Identification and characterization of jak2 pseudokinase domain small molecule binders. ACS Medicinal Chemistry Letters, 8:618-621, May 2017. URL: https://doi.org/10.1021/acsmedchemlett.7b00153, doi:10.1021/acsmedchemlett.7b00153. This article has 49 citations and is from a peer-reviewed journal.

13. (qian2011nuclearjak2form pages 1-2): Cui‐Juan Qian, Jun Yao, and Jian‐Min Si. Nuclear jak2: form and function in cancer. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology, Sep 2011. URL: https://doi.org/10.1002/ar.21443, doi:10.1002/ar.21443. This article has 30 citations.

14. (qian2011nuclearjak2form pages 3-5): Cui‐Juan Qian, Jun Yao, and Jian‐Min Si. Nuclear jak2: form and function in cancer. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology, Sep 2011. URL: https://doi.org/10.1002/ar.21443, doi:10.1002/ar.21443. This article has 30 citations.

15. (qian2011nuclearjak2form pages 7-7): Cui‐Juan Qian, Jun Yao, and Jian‐Min Si. Nuclear jak2: form and function in cancer. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology, Sep 2011. URL: https://doi.org/10.1002/ar.21443, doi:10.1002/ar.21443. This article has 30 citations.

16. (silvennoinen2013newinsightsinto pages 1-2): Olli Silvennoinen, Daniela Ungureanu, Yashavanthi Niranjan, Henrik Hammaren, Rajintha Bandaranayake, and Stevan R. Hubbard. New insights into the structure and function of the pseudokinase domain in jak2. Biochemical Society transactions, 41 4:1002-7, Aug 2013. URL: https://doi.org/10.1042/bst20130005, doi:10.1042/bst20130005. This article has 62 citations and is from a peer-reviewed journal.

17. (silvennoinen2013newinsightsinto pages 2-3): Olli Silvennoinen, Daniela Ungureanu, Yashavanthi Niranjan, Henrik Hammaren, Rajintha Bandaranayake, and Stevan R. Hubbard. New insights into the structure and function of the pseudokinase domain in jak2. Biochemical Society transactions, 41 4:1002-7, Aug 2013. URL: https://doi.org/10.1042/bst20130005, doi:10.1042/bst20130005. This article has 62 citations and is from a peer-reviewed journal.

18. (silvennoinen2013newinsightsinto pages 3-5): Olli Silvennoinen, Daniela Ungureanu, Yashavanthi Niranjan, Henrik Hammaren, Rajintha Bandaranayake, and Stevan R. Hubbard. New insights into the structure and function of the pseudokinase domain in jak2. Biochemical Society transactions, 41 4:1002-7, Aug 2013. URL: https://doi.org/10.1042/bst20130005, doi:10.1042/bst20130005. This article has 62 citations and is from a peer-reviewed journal.

19. (vainchenker2005auniqueactivating pages 1-2): William Vainchenker and Stefan N. Constantinescu. A unique activating mutation in jak2 (v617f) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology, 2005:195-200, Jan 2005. URL: https://doi.org/10.1182/asheducation-2005.1.195, doi:10.1182/asheducation-2005.1.195. This article has 171 citations and is from a peer-reviewed journal.

20. (williams2009dissectingspecificityin pages 1-3): Neal K. Williams, Rebecca S. Bamert, Onisha Patel, Christina Wang, Patricia M. Walden, Andrew F. Wilks, Emmanuelle Fantino, Jamie Rossjohn, and Isabelle S. Lucet. Dissecting specificity in the janus kinases: the structures of jak-specific inhibitors complexed to the jak1 and jak2 protein tyrosine kinase domains. Journal of molecular biology, 387 1:219-32, Mar 2009. URL: https://doi.org/10.1016/j.jmb.2009.01.041, doi:10.1016/j.jmb.2009.01.041. This article has 286 citations and is from a domain leading peer-reviewed journal.

21. (williams2009dissectingspecificityin pages 12-13): Neal K. Williams, Rebecca S. Bamert, Onisha Patel, Christina Wang, Patricia M. Walden, Andrew F. Wilks, Emmanuelle Fantino, Jamie Rossjohn, and Isabelle S. Lucet. Dissecting specificity in the janus kinases: the structures of jak-specific inhibitors complexed to the jak1 and jak2 protein tyrosine kinase domains. Journal of molecular biology, 387 1:219-32, Mar 2009. URL: https://doi.org/10.1016/j.jmb.2009.01.041, doi:10.1016/j.jmb.2009.01.041. This article has 286 citations and is from a domain leading peer-reviewed journal.

22. (williams2009dissectingspecificityin pages 5-7): Neal K. Williams, Rebecca S. Bamert, Onisha Patel, Christina Wang, Patricia M. Walden, Andrew F. Wilks, Emmanuelle Fantino, Jamie Rossjohn, and Isabelle S. Lucet. Dissecting specificity in the janus kinases: the structures of jak-specific inhibitors complexed to the jak1 and jak2 protein tyrosine kinase domains. Journal of molecular biology, 387 1:219-32, Mar 2009. URL: https://doi.org/10.1016/j.jmb.2009.01.041, doi:10.1016/j.jmb.2009.01.041. This article has 286 citations and is from a domain leading peer-reviewed journal.

23. (bandaranayake2012crystalstructuresof pages 6-7): Rajintha M Bandaranayake, Daniela Ungureanu, Yibing Shan, David E Shaw, Olli Silvennoinen, and Stevan R Hubbard. Crystal structures of the jak2 pseudokinase domain and the pathogenic mutant v617f. Nature Structural &amp; Molecular Biology, 19:754-759, Jul 2012. URL: https://doi.org/10.1038/nsmb.2348, doi:10.1038/nsmb.2348. This article has 287 citations.

24. (bandaranayake2012crystalstructuresof pages 7-9): Rajintha M Bandaranayake, Daniela Ungureanu, Yibing Shan, David E Shaw, Olli Silvennoinen, and Stevan R Hubbard. Crystal structures of the jak2 pseudokinase domain and the pathogenic mutant v617f. Nature Structural &amp; Molecular Biology, 19:754-759, Jul 2012. URL: https://doi.org/10.1038/nsmb.2348, doi:10.1038/nsmb.2348. This article has 287 citations.

25. (kesarwani2015targetingsubstratesitein pages 2-4): M. Kesarwani, E. Huber, Zachary Kincaid, Chris R. Evelyn, J. Biesiada, M. Rance, M. Thapa, N. Shah, J. Meller, Yi Zheng, and M. Azam. Targeting substrate-site in jak2 kinase prevents emergence of genetic resistance. Scientific Reports, Sep 2015. URL: https://doi.org/10.1038/srep14538, doi:10.1038/srep14538. This article has 65 citations and is from a poor quality or predatory journal.

26. (lin2018anovelselective pages 1-2): Tony Eight Lin, Wei-Chun HuangFu, Min-Wu Chao, Tzu-Ying Sung, Chao-Di Chang, Yi-Ying Chen, Jui-Hua Hsieh, Huang-Ju Tu, Han-Li Huang, Shiow-Lin Pan, and Kai-Cheng Hsu. A novel selective jak2 inhibitor identified using pharmacological interactions. Frontiers in Pharmacology, Dec 2018. URL: https://doi.org/10.3389/fphar.2018.01379, doi:10.3389/fphar.2018.01379. This article has 32 citations and is from a peer-reviewed journal.

27. (lin2018anovelselective pages 10-11): Tony Eight Lin, Wei-Chun HuangFu, Min-Wu Chao, Tzu-Ying Sung, Chao-Di Chang, Yi-Ying Chen, Jui-Hua Hsieh, Huang-Ju Tu, Han-Li Huang, Shiow-Lin Pan, and Kai-Cheng Hsu. A novel selective jak2 inhibitor identified using pharmacological interactions. Frontiers in Pharmacology, Dec 2018. URL: https://doi.org/10.3389/fphar.2018.01379, doi:10.3389/fphar.2018.01379. This article has 32 citations and is from a peer-reviewed journal.

28. (lupardus2014structureofthe pages 5-6): Patrick J. Lupardus, Mark Ultsch, Heidi Wallweber, Pawan Bir Kohli, Adam R. Johnson, and Charles Eigenbrot. Structure of the pseudokinase–kinase domains from protein kinase tyk2 reveals a mechanism for janus kinase (jak) autoinhibition. Proceedings of the National Academy of Sciences, 111:8025-8030, May 2014. URL: https://doi.org/10.1073/pnas.1401180111, doi:10.1073/pnas.1401180111. This article has 228 citations.

29. (min2015structuralandfunctional pages 1-2): Xiaoshan Min, Daniela Ungureanu, Sarah Maxwell, Henrik Hammarén, Steve Thibault, Ellin-Kristina Hillert, Merrill Ayres, Brad Greenfield, John Eksterowicz, Chris Gabel, Nigel Walker, Olli Silvennoinen, and Zhulun Wang. Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290:27261-27270, Nov 2015. URL: https://doi.org/10.1074/jbc.m115.672048, doi:10.1074/jbc.m115.672048. This article has 108 citations and is from a domain leading peer-reviewed journal.

30. (min2015structuralandfunctional pages 2-3): Xiaoshan Min, Daniela Ungureanu, Sarah Maxwell, Henrik Hammarén, Steve Thibault, Ellin-Kristina Hillert, Merrill Ayres, Brad Greenfield, John Eksterowicz, Chris Gabel, Nigel Walker, Olli Silvennoinen, and Zhulun Wang. Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290:27261-27270, Nov 2015. URL: https://doi.org/10.1074/jbc.m115.672048, doi:10.1074/jbc.m115.672048. This article has 108 citations and is from a domain leading peer-reviewed journal.

31. (perner2019rolesofjak2 pages 1-3): Florian Perner, Caroline Perner, Thomas Ernst, and Florian H. Heidel. Roles of jak2 in aging, inflammation, hematopoiesis and malignant transformation. Cells, 8:854, Aug 2019. URL: https://doi.org/10.3390/cells8080854, doi:10.3390/cells8080854. This article has 226 citations and is from a peer-reviewed journal.

32. (perner2019rolesofjak2 pages 5-7): Florian Perner, Caroline Perner, Thomas Ernst, and Florian H. Heidel. Roles of jak2 in aging, inflammation, hematopoiesis and malignant transformation. Cells, 8:854, Aug 2019. URL: https://doi.org/10.3390/cells8080854, doi:10.3390/cells8080854. This article has 226 citations and is from a peer-reviewed journal.

33. (perner2019rolesofjak2 pages 7-9): Florian Perner, Caroline Perner, Thomas Ernst, and Florian H. Heidel. Roles of jak2 in aging, inflammation, hematopoiesis and malignant transformation. Cells, 8:854, Aug 2019. URL: https://doi.org/10.3390/cells8080854, doi:10.3390/cells8080854. This article has 226 citations and is from a peer-reviewed journal.